{"id":745215,"date":"2015-04-20T07:00:00","date_gmt":"2015-04-20T07:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/tetralogic-and-merck-to-collaborate-on-the-evaluation-of-birinapant-in-combination-with-keytruda-pembrolizumab-in-solid-tumors\/"},"modified":"2025-11-07T01:25:15","modified_gmt":"2025-11-07T06:25:15","slug":"tetralogic-and-merck-to-collaborate-on-the-evaluation-of-birinapant-in-combination-with-keytruda-pembrolizumab-in-solid-tumors","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/tetralogic-and-merck-to-collaborate-on-the-evaluation-of-birinapant-in-combination-with-keytruda-pembrolizumab-in-solid-tumors\/","title":{"rendered":"TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA\u00ae (pembrolizumab) in Solid Tumors"},"content":{"rendered":"<p>MALVERN, Pa. &amp; KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;TetraLogic Pharmaceuticals Corporation (Nasdaq: TLOG), a clinical-stage<br \/>\n      biopharmaceutical company focused on discovering and developing novel<br \/>\n      small molecule therapeutics in oncology and infectious diseases, and<br \/>\n      Merck (NYSE:MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today they have entered into an oncology clinical study<br \/>\n      collaboration. The companies will collaborate on a Phase 1 study to<br \/>\n      evaluate the safety and efficacy of birinapant, TetraLogic\u2019s<br \/>\n      SMAC-mimetic, in combination with KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s<br \/>\n      anti-PD-1 therapy, in patients with relapsed or refractory solid tumors.<br \/>\n      The study is expected to begin in late 2015.\n    <\/p>\n<p>\n      KEYTRUDA and birinapant target different elements of cancer\u2019s block<br \/>\n      against the immune system. TetraLogic\u2019s birinapant (TL32711) is a<br \/>\n      potent, bivalent SMAC-mimetic that binds with differential affinity to<br \/>\n      multiple members of the IAP family in order to re-establish the immune<br \/>\n      system\u2019s ability to kill abnormal cells via an extracellular TNF signal.<br \/>\n      Merck\u2019s KEYTRUDA is a humanized monoclonal antibody that blocks the<br \/>\n      interaction between PD-1 (programmed death receptor-1) and its ligands,<br \/>\n      PD-L1 and PD-L2. The proposed collaboration is based on preclinical data<br \/>\n      that suggest SMAC-mimetics have the potential to enhance existing<br \/>\n      immuno-oncology agents, such as KEYTRUDA.\n    <\/p>\n<p>\n      \u201cWe are very excited to work with Merck to evaluate birinapant in<br \/>\n      combination with KEYTRUDA,\u201d said J. Kevin Buchi, President and Chief<br \/>\n      Executive Officer of TetraLogic. \u201cBoth molecules are designed to help<br \/>\n      the body\u2019s immune system better attack cancer cells, and we think the<br \/>\n      combination could be very promising.\u201d\n    <\/p>\n<p>\n      \u201cWe are establishing a broad base of clinical evidence with our<br \/>\n      anti-PD-1 therapy, KEYTRUDA, as monotherapy across different types of<br \/>\n      cancer,\u201d said Dr. Eric Rubin, vice president and therapeutic area head,<br \/>\n      oncology early-stage development, Merck Research Laboratories. \u201cWe<br \/>\n      believe there is great potential to advance our clinical program and the<br \/>\n      field of immuno-oncology research through strategic collaborations and<br \/>\n      synergistic combinations, such as with KEYTRUDA and birinapant.\u201d\n    <\/p>\n<p>\n      Under the terms of the agreement, TetraLogic and Merck, through<br \/>\n      subsidiaries<b>,<\/b> will collaborate on an initial Phase 1<br \/>\n      dose-escalation study of birinapant in combination with KEYTRUDA in<br \/>\n      patients with relapsed or refractory solid tumors. TetraLogic will<br \/>\n      sponsor and fund the study and Merck will provide KEYTRUDA. The<br \/>\n      companies have formed a Joint Development Committee to collaboratively<br \/>\n      oversee the conduct of the study. Results from the study will be used to<br \/>\n      determine the path for further clinical development of the combination.\n    <\/p>\n<p>\n      <b>About Birinapant<\/b>\n    <\/p>\n<p>\n      Cancer and chronically infected cells are able to evade a critical<br \/>\n      mechanism by which the immune system normally kills abnormal or<br \/>\n      genetically modified cells. They do this by upregulating the Inhibitors<br \/>\n      of Apoptosis (IAP) Proteins. Birinapant (TL32711) is a potent, bivalent<br \/>\n      SMAC-mimetic that binds with differential affinity to multiple members<br \/>\n      of the IAP family in order to re-establish the immune system\u2019s ability<br \/>\n      to kill abnormal cells via an extracellular TNF signal. Birinapant has<br \/>\n      been studied in over 350 patients, and is currently in Phase 1 and Phase<br \/>\n      2 trials for Myelodysplastic Syndrome (MDS), Ovarian Cancer and<br \/>\n      Hepatitis B.\n    <\/p>\n<p>\n      <b>About KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b> (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      KEYTRUDA (pembrolizumab) is a humanized monoclonal antibody that blocks<br \/>\n      the interaction between PD-1 and its ligands, PD-L1 and PD-L2. By<br \/>\n      binding to the PD-1 receptor and blocking the interaction with the<br \/>\n      receptor ligands, KEYTRUDA releases the PD-1 pathway-mediated inhibition<br \/>\n      of the immune response, including the anti-tumor immune response.\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the United States at a dose of 2 mg\/kg<br \/>\n      administered as an intravenous infusion over 30 minutes every three<br \/>\n      weeks for the treatment of patients with unresectable or metastatic<br \/>\n      melanoma and disease progression following ipilimumab and, if BRAF V600<br \/>\n      mutation positive, a BRAF inhibitor. This indication is approved under<br \/>\n      accelerated approval based on tumor response rate and durability of<br \/>\n      response. An improvement in survival or disease-related symptoms has not<br \/>\n      yet been established. Continued approval for this indication may be<br \/>\n      contingent upon verification and description of clinical benefit in the<br \/>\n      confirmatory trials.\n    <\/p>\n<p>\n      Merck is advancing a broad and fast-growing clinical development program<br \/>\n      for KEYTRUDA with more than 85 clinical trials \u2013 across more than 30<br \/>\n      tumor types and over 14,000 patients \u2013 both as a monotherapy and in<br \/>\n      combination with other therapies.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b>\n    <\/p>\n<p>\n      Pneumonitis occurred in 12 (2.9%) of 411 patients with advanced melanoma<br \/>\n      receiving KEYTRUDA (the approved indication in the United States),<br \/>\n      including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) patients,<br \/>\n      respectively. Monitor patients for signs and symptoms of pneumonitis.<br \/>\n      Evaluate suspected pneumonitis with radiographic imaging. Administer<br \/>\n      corticosteroids for Grade 2 or greater pneumonitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients, including Grade 2 or 3 cases in 1 (0.2%) and 2 (0.5%) patients<br \/>\n      respectively, receiving KEYTRUDA. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis (including autoimmune hepatitis) occurred in 2 (0.5%) of 411<br \/>\n      patients, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients, including a Grade 2<br \/>\n      case in 1 and a Grade 4 case in 1 (0.2% each) patient, receiving<br \/>\n      KEYTRUDA. Monitor for signs and symptoms of hypophysitis. Administer<br \/>\n      corticosteroids for Grade 2 or greater hypophysitis. Withhold KEYTRUDA<br \/>\n      for Grade 2; withhold or discontinue for Grade 3; and permanently<br \/>\n      discontinue KEYTRUDA for Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Nephritis occurred in 3 (0.7%) patients receiving KEYTRUDA, consisting<br \/>\n      of one case of Grade 2 autoimmune nephritis (0.2%) and two cases of<br \/>\n      interstitial nephritis with renal failure (0.5%), one Grade 3 and one<br \/>\n      Grade 4. Monitor patients for changes in renal function. Administer<br \/>\n      corticosteroids for Grade 2 or greater nephritis. Withhold KEYTRUDA for<br \/>\n      Grade 2; permanently discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients, including Grade 2<br \/>\n      or 3 cases in 2 (0.5%) and 1 (0.2%) patients respectively, receiving<br \/>\n      KEYTRUDA. Hypothyroidism occurred in 34 (8.3%) of 411 patients,<br \/>\n      including a Grade 3 case in 1 (0.2%) patient, receiving KEYTRUDA.<br \/>\n      Thyroid disorders can occur at any time during treatment. Monitor<br \/>\n      patients for changes in thyroid function (at the start of treatment,<br \/>\n      periodically during treatment, and as indicated based on clinical<br \/>\n      evaluation) and for clinical signs and symptoms of thyroid disorders.<br \/>\n      Administer corticosteroids for Grade 3 or greater hyperthyroidism.<br \/>\n      Withhold KEYTRUDA for Grade 3; permanently discontinue KEYTRUDA for<br \/>\n      Grade 4 hyperthyroidism. Isolated hypothyroidism may be managed with<br \/>\n      replacement therapy without treatment interruption and without<br \/>\n      corticosteroids.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      The following clinically significant, immune-mediated adverse reactions<br \/>\n      occurred in less than 1% of patients treated with KEYTRUDA: exfoliative<br \/>\n      dermatitis, uveitis, arthritis, myositis, pancreatitis, hemolytic<br \/>\n      anemia, partial seizures arising in a patient with inflammatory foci in<br \/>\n      brain parenchyma, adrenal insufficiency, myasthenic syndrome, optic<br \/>\n      neuritis, and rhabdomyolysis.\n    <\/p>\n<p>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Restart KEYTRUDA if the adverse reaction remains at Grade 1 or<br \/>\n      less. Permanently discontinue KEYTRUDA for any severe or Grade 3<br \/>\n      immune-mediated adverse reaction that recurs and for any<br \/>\n      life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA may cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      For the treatment of advanced melanoma, KEYTRUDA was discontinued for<br \/>\n      adverse reactions in 6% of 89 patients who received the recommended dose<br \/>\n      of 2 mg\/kg and 9% of 411 patients across all doses studied. Serious<br \/>\n      adverse reactions occurred in 36% of patients receiving KEYTRUDA. The<br \/>\n      most frequent serious adverse drug reactions reported in 2% or more of<br \/>\n      patients were renal failure, dyspnea, pneumonia, and cellulitis.\n    <\/p>\n<p>\n      The most common adverse reactions (reported in \u226520% of patients) were<br \/>\n      fatigue (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%),<br \/>\n      decreased appetite (26%), constipation (21%), arthralgia (20%), and<br \/>\n      diarrhea (20%).\n    <\/p>\n<p>\n      The recommended dose of KEYTRUDA is 2 mg\/kg administered as an<br \/>\n      intravenous infusion over 30 minutes every three weeks until disease<br \/>\n      progression or unacceptable toxicity. No formal pharmacokinetic drug<br \/>\n      interaction studies have been conducted with KEYTRUDA. It is not known<br \/>\n      whether KEYTRUDA is excreted in human milk. Because many drugs are<br \/>\n      excreted in human milk, instruct women to discontinue nursing during<br \/>\n      treatment with KEYTRUDA. Safety and effectiveness of KEYTRUDA have not<br \/>\n      been established in pediatric patients.\n    <\/p>\n<p>\n      <b>Merck\u2019s Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into biomedical<br \/>\n      innovations to help people with cancer worldwide. For Merck Oncology,<br \/>\n      helping people fight cancer is our passion, supporting accessibility to<br \/>\n      our cancer medicines is our commitment, and pursuing research in<br \/>\n      immuno-oncology is our focus to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51082764&amp;newsitemid=20150420005234&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=a73fc2a260b8ff2b7f9c8cf23b870dce\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside of the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to healthcare through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2F&amp;esheet=51082764&amp;newsitemid=20150420005234&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=479acc379aa0762cbeffc88fceef2e91\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Fmerck&amp;esheet=51082764&amp;newsitemid=20150420005234&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=38062b1d89c28c6c00b990462048be93\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51082764&amp;newsitemid=20150420005234&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=48cfe0c635492d4fa6cfa30364218d4b\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.youtube.com%2Fuser%2FMerck&amp;esheet=51082764&amp;newsitemid=20150420005234&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=2324bb6e27fbbce4f80f1cc84f3f60d7\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>About TetraLogic Pharmaceuticals Corporation<\/b>\n    <\/p>\n<p>\n      TetraLogic is a clinical-stage biopharmaceutical company focused on<br \/>\n      discovering and developing novel small molecule therapeutics in oncology<br \/>\n      and infectious diseases. TetraLogic has two clinical-stage product<br \/>\n      candidates in development: birinapant and SHAPE. Birinapant is currently<br \/>\n      being tested in Phase 1 and Phase 2 clinical trials for hematological<br \/>\n      malignancies and solid tumors, and is also being tested in a Phase 1b\/2a<br \/>\n      clinical trial in hepatitis B. SHAPE is currently being tested in a<br \/>\n      Phase 2 clinical trial for early-stage cutaneous T-cell lymphoma.\n    <\/p>\n<p>\n      <b>TetraLogic Forward Looking Statement<\/b>\n    <\/p>\n<p>\n      Some of the statements in this release are forward looking statements<br \/>\n      within the meaning of Section 27A of the Securities Act of 1933, Section<br \/>\n      21E of the Securities Exchange Act of 1934 and the Private Securities<br \/>\n      Litigation Reform Act of 1995, which involve risks and uncertainties.<br \/>\n      These statements relate to future events or TetraLogic\u2019s pre-clinical<br \/>\n      and clinical development of birinapant, SHAPE and other clinical<br \/>\n      programs, future expectations, plans and prospects. Although TetraLogic<br \/>\n      believes that the expectations reflected in such forward-looking<br \/>\n      statements are reasonable as of the date made, expectations may prove to<br \/>\n      have been materially different from the results expressed or implied by<br \/>\n      such forward-looking statements. TetraLogic has attempted to identify<br \/>\n      forward looking statements by terminology including \u2018\u2018believes,\u2019\u2019<br \/>\n      \u2018\u2018estimates,\u2019\u2019 \u2018\u2018anticipates,\u2019\u2019 \u2018\u2018expects,\u2019\u2019 \u2018\u2018plans,\u2019\u2019 \u2018\u2018projects,\u2019\u2019<br \/>\n      \u2018\u2018intends,\u2019\u2019 \u2018\u2018potential,\u2019\u2019 \u2018\u2018may,\u2019\u2019 \u2018\u2018could,\u2019\u2019 \u2018\u2018might,\u2019\u2019 \u2018\u2018will,\u2019\u2019<br \/>\n      \u2018\u2018should,\u2019\u2019 \u2018\u2018approximately\u2019\u2019 or other words that convey uncertainty of<br \/>\n      future events or outcomes to identify these forward-looking statements.<br \/>\n      These statements are only predictions and involve known and unknown<br \/>\n      risks, uncertainties, and other factors, including those discussed under<br \/>\n      the heading \u201cRisk Factors\u201d in our Annual Report on Form 10-K filed with<br \/>\n      the U.S. Securities and Exchange Commission (SEC) on February 26, 2015.<br \/>\n      Any forward-looking statements contained in this release speak only as<br \/>\n      of its date. We undertake no obligation to update any forward-looking<br \/>\n      statements contained in this release to reflect events or circumstances<br \/>\n      occurring after its date or to reflect the occurrence of unanticipated<br \/>\n      events.\n    <\/p>\n<p>\n      <b>Merck Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include, but are not limited to, general<br \/>\n      industry conditions and competition; general economic factors, including<br \/>\n      interest rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and healthcare legislation in the<br \/>\n      United States and internationally; global trends toward healthcare cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2014 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51082764&amp;newsitemid=20150420005234&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=6&amp;md5=5aa855d9b3d7bc7848c810c4c949ad7c\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51082764&amp;newsitemid=20150420005234&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=7&amp;md5=4b76b5c95194d148e6848a1bc0476c91\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and the Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51082764&amp;newsitemid=20150420005234&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=8&amp;md5=ca7a62bf1203b14fb00ed5f1cb420367\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a>\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20150420005234r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" \/><span class=\"bwct31415\" \/><\/span><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">Photos\/Multimedia Gallery Available: <\/span><span id=\"mmgallerylink-link\"><a href=\"http:\/\/www.businesswire.com\/multimedia\/home\/20150420005234\/en\/\" rel=\"nofollow\">http:\/\/www.businesswire.com\/multimedia\/home\/20150420005234\/en\/<\/a><\/span><\/p>\n<p>       Merck Media Relations:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Claire        Mulhearn, 908-236-1118<br \/>or<br \/>Merck Investor Relations:<br \/>Justin        Holko, 908-740-1879<br \/>or<br \/>TetraLogic Investor Relations:<br \/>Pete        A. Meyers, 610-889-9900, x103<br \/><a href=\"mailto:pete.meyers@tlog.com\">pete.meyers@tlog.com<\/a>     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>TetraLogic Pharmaceuticals Corporation (Nasdaq: TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today they have entered into an oncology clinical study collaboration. The companies will collaborate on a Phase 1 study to evaluate the safety and efficacy of birinapant, TetraLogic\u2019s SMAC-mimetic, in combination with KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s anti-PD-1 therapy, in patients with relapsed or refractory solid tumors. The study is expected to begin in late 2015. KEYTRUDA and birinapant target different elements of cancer\u2019s block against the immune system. TetraLogic\u2019s birinapant (TL32711) is a potent, bivalent SMAC-mimetic that binds with differential affinity to multiple members of the IAP family in order to re-establish the immune system\u2019s ability to kill abnormal cells via an extracellular<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,137,138,55,289],"class_list":["post-745215","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-oncology","tag-oncology-newsroom","tag-prescription-medicine-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA\u00ae (pembrolizumab) in Solid Tumors - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/tetralogic-and-merck-to-collaborate-on-the-evaluation-of-birinapant-in-combination-with-keytruda-pembrolizumab-in-solid-tumors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA\u00ae (pembrolizumab) in Solid Tumors - Merck.com\" \/>\n<meta property=\"og:description\" content=\"TetraLogic Pharmaceuticals Corporation (Nasdaq: TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today they have entered into an oncology clinical study collaboration. The companies will collaborate on a Phase 1 study to evaluate the safety and efficacy of birinapant, TetraLogic\u2019s SMAC-mimetic, in combination with KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s anti-PD-1 therapy, in patients with relapsed or refractory solid tumors. The study is expected to begin in late 2015. KEYTRUDA and birinapant target different elements of cancer\u2019s block against the immune system. TetraLogic\u2019s birinapant (TL32711) is a potent, bivalent SMAC-mimetic that binds with differential affinity to multiple members of the IAP family in order to re-establish the immune system\u2019s ability to kill abnormal cells via an extracellular\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/tetralogic-and-merck-to-collaborate-on-the-evaluation-of-birinapant-in-combination-with-keytruda-pembrolizumab-in-solid-tumors\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:25:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/tetralogic-and-merck-to-collaborate-on-the-evaluation-of-birinapant-in-combination-with-keytruda-pembrolizumab-in-solid-tumors\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/tetralogic-and-merck-to-collaborate-on-the-evaluation-of-birinapant-in-combination-with-keytruda-pembrolizumab-in-solid-tumors\\\/\",\"name\":\"TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA\u00ae (pembrolizumab) in Solid Tumors - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-04-20T07:00:00+00:00\",\"dateModified\":\"2025-11-07T06:25:15+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/tetralogic-and-merck-to-collaborate-on-the-evaluation-of-birinapant-in-combination-with-keytruda-pembrolizumab-in-solid-tumors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/tetralogic-and-merck-to-collaborate-on-the-evaluation-of-birinapant-in-combination-with-keytruda-pembrolizumab-in-solid-tumors\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/tetralogic-and-merck-to-collaborate-on-the-evaluation-of-birinapant-in-combination-with-keytruda-pembrolizumab-in-solid-tumors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA\u00ae (pembrolizumab) in Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA\u00ae (pembrolizumab) in Solid Tumors - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/tetralogic-and-merck-to-collaborate-on-the-evaluation-of-birinapant-in-combination-with-keytruda-pembrolizumab-in-solid-tumors\/","og_locale":"en_US","og_type":"article","og_title":"TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA\u00ae (pembrolizumab) in Solid Tumors - Merck.com","og_description":"TetraLogic Pharmaceuticals Corporation (Nasdaq: TLOG), a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule therapeutics in oncology and infectious diseases, and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today they have entered into an oncology clinical study collaboration. The companies will collaborate on a Phase 1 study to evaluate the safety and efficacy of birinapant, TetraLogic\u2019s SMAC-mimetic, in combination with KEYTRUDA\u00ae (pembrolizumab), Merck\u2019s anti-PD-1 therapy, in patients with relapsed or refractory solid tumors. The study is expected to begin in late 2015. KEYTRUDA and birinapant target different elements of cancer\u2019s block against the immune system. TetraLogic\u2019s birinapant (TL32711) is a potent, bivalent SMAC-mimetic that binds with differential affinity to multiple members of the IAP family in order to re-establish the immune system\u2019s ability to kill abnormal cells via an extracellular","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/tetralogic-and-merck-to-collaborate-on-the-evaluation-of-birinapant-in-combination-with-keytruda-pembrolizumab-in-solid-tumors\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:25:15+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/tetralogic-and-merck-to-collaborate-on-the-evaluation-of-birinapant-in-combination-with-keytruda-pembrolizumab-in-solid-tumors\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/tetralogic-and-merck-to-collaborate-on-the-evaluation-of-birinapant-in-combination-with-keytruda-pembrolizumab-in-solid-tumors\/","name":"TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA\u00ae (pembrolizumab) in Solid Tumors - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-04-20T07:00:00+00:00","dateModified":"2025-11-07T06:25:15+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/tetralogic-and-merck-to-collaborate-on-the-evaluation-of-birinapant-in-combination-with-keytruda-pembrolizumab-in-solid-tumors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/tetralogic-and-merck-to-collaborate-on-the-evaluation-of-birinapant-in-combination-with-keytruda-pembrolizumab-in-solid-tumors\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/tetralogic-and-merck-to-collaborate-on-the-evaluation-of-birinapant-in-combination-with-keytruda-pembrolizumab-in-solid-tumors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"TetraLogic and Merck to Collaborate on the Evaluation of Birinapant in Combination with KEYTRUDA\u00ae (pembrolizumab) in Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"31f2d326-00a1-480b-b571-48d49983ab4a","news_item_aria_label":"","media_files":[{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2015\/04\/1\/merck_logo.jpg","size":"21167","File Upload":""},{"path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_events\/2015\/04\/1\/TetraLogic_Logo.jpg","size":"97100","File Upload":""}],"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745215","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745215\/revisions"}],"predecessor-version":[{"id":3674654,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745215\/revisions\/3674654"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745215"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745215"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}